359600-10-5
Chemical Structure
RNPA1000
- CAS No.: 359600-10-5
- Formula:C23H18BrN3O3
- Molecular Weight:464.31
IUPAC Name: (E)-4-(3-(3-((3-bromophenyl)amino)-2-cyano-3-oxoprop-1-en-1-yl)-2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid
InChIKey: WQCMDUBFZYCGMI-WOJGMQOQSA-N
SMILES: O=C(O)C1=CC=C(N2C(C)=C(/C=C(C#N)/C(NC3=CC=CC(Br)=C3)=O)C=C2C)C=C1
Biological Activity: RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC50 of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RNPA1000 | 98.15% | RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC50 of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RNPA1000 (Standard) | ≥98% | Phenyl salicylate (Standard) is the analytical standard of Phenyl salicylate. This product is intended for research and analytical applications. Phenyl salicylate (PS) has antibacterial activity when hydrolyzed in small intestine and is often used as nervous system inhibitor and intestinal preservative. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Eidem TM, et al. Drug-eluting cements for hard tissue repair: a comparative study using vancomycin and RNPA1000 to inhibit growth of Staphylococcus aureus. J Biomater Appl. 2014 Apr;28(8):1235-46. [Content Brief]
- [2]. Eidem TM, et al. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28. [Content Brief]
- [3]. Patrick D Olson, et al. Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular mRNA turnover, exhibit antimicrobial activity, and attenuate pathogenesis. PLoS Pathog. 2011 Feb 10;7(2):e1001287. [Content Brief]
Keywords
